XML 222 R90.htm IDEA: XBRL DOCUMENT v3.25.0.1

Commitments and Contingencies - Narrative (Details) - USD ($)		1 Months Ended	12 Months Ended
	Apr. 29, 2020	Jul. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Nov. 13, 2024	Sep. 30, 2024	Jul. 31, 2024	May 31, 2024	May 29, 2020
Other Commitments
Research and development expense			$ 534,480,000	$ 666,563,000	$ 651,496,000
Milestone payable			11,025,000	2,500,000
Accrued royalties			8,953,000	74,111,000
Accounts payable and accrued expenses
Other Commitments
Milestone payments triggered						$ 11,000,000
Censa
Other Commitments
Asset acquisition, development and regulatory milestones										$ 109,000,000
Development milestone obligation payments made				30,000,000
Development milestone obligation cash payments made				$ 400,000
Shares issued for milestone payment				657,462
Censa | Maximum
Other Commitments
Asset acquisition, milestone, amount										217,500,000
Asset acquisition, net sales milestone										$ 160,000,000
Former Censa Securityholders
Other Commitments
Development milestone obligation payments made				$ 30,000,000
Development milestone obligation cash payments made				$ 400,000
Shares issued for milestone payment				657,462
Agilis Merger Agreement | Marathon
Other Commitments
Development milestone payment obligations					$ 50,000,000
SMA License Agreement | SMA Foundation
Other Commitments
Royalty expense since inception			52,500,000
Royalty payments			52,500,000
Potential royalty payments due on net product sales			0
Agilis
Other Commitments
Development milestone payments which the entity is obligated to pay			40,000,000
Potential developmental and regulatory milestones			0
Potential sales milestones	$ 150,000,000		50,000,000
Milestone obligation payments made		$ 50,000,000
Development milestone obligation payments made			$ 2,400,000
Agilis | Minimum
Other Commitments
Product sales (as a percent)	2.00%		2.00%
Agilis | Maximum
Other Commitments
Development milestone payment obligations			$ 60,000,000
Priority review voucher amount			535,000,000
Potential sales milestones			$ 150,000,000
Product sales (as a percent)	6.00%		6.00%
Development milestone payment obligations, net of cancellation and forfeiture			$ 20,000,000
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture			361,000,000
Agilis | Accounts payable and accrued expenses
Other Commitments
Milestone payable			11,000,000
Agilis | Agilis Merger Agreement
Other Commitments
Development milestone payment obligations			40,000,000
Agilis | Rights Exchange Agreement
Other Commitments
Contingent liability cancellation and forfeiture of potential milestone payments	$ 174,000,000
Development milestone payment obligations, cancellation and forfeiture	$ 37,600,000
Contingent liability, cancellation and forfeiture			211,600,000
BioElectron | Maximum
Other Commitments
Development milestone payment obligations			200,000,000
Development and Regulatory Milestones
Other Commitments
Potential developmental and regulatory milestones			0
Regulatory Milestones
Other Commitments
Research and development expense			65,000,000
Regulatory Milestones | Former Censa Securityholders
Other Commitments
Milestone payments triggered							$ 25,000,000	$ 25,000,000	$ 15,000,000
Regulatory Milestones | Agilis
Other Commitments
Milestone obligation payments made			$ 20,000,000

X

- Definition

Asset Acquisition, Development And Regulatory Milestones

+ References

No definition available.

+ Details

Name:	ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Asset Acquisition, Milestone, Amount

+ References

No definition available.

+ Details

Name:	ptct_AssetAcquisitionMilestoneAmount
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Asset Acquisition, Net Sales Milestone

+ References

No definition available.

+ Details

Name:	ptct_AssetAcquisitionNetSalesMilestone
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Contingent Liability, Cancellation and Forfeiture

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityCancellationAndForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of potential payments which may be due for developmental and regulatory milestones if achieved.

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsDevelopmentalAndRegulatoryMilestones
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
Namespace Prefix:	ptct_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of development milestone obligation payments made during the period.

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestoneObligationPaymentsMade
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of development milestone obligation cash payments made during the period.

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestoneObligationPaymentsMadeCash
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestonePaymentObligations
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Development Milestone Payment Obligations, Cancellation and Forfeiture

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Development Milestone Payment Obligations, net of cancellation and forfeiture

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of recorded milestone payments payable.

+ References

No definition available.

+ Details

Name:	ptct_MilestonePayable
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Milestone payment which the entity is obliged to pay upon regulatory approval

+ References

No definition available.

+ Details

Name:	ptct_MilestonePotentialAchievementsRegulatoryApproval
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of cash outflow for milestone obligations paid.

+ References

No definition available.

+ Details

Name:	ptct_PaymentOfMilestoneObligation
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ptct_PotentialRoyaltiesDueNetProductSales
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number of shares issued during the period as a result of a milestone payable.

+ References

No definition available.

+ Details

Name:	ptct_StockIssuedDuringPeriodSharesMilestonePayable
Namespace Prefix:	ptct_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 8
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-8

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ptct_CensaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ptct_FormerCensaSecurityholdersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=ptct_SmaFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptct_RightsExchangeAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityDevelopmentandRegulatoryMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=ptct_LiabilityRegulatoryMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: